[Basic results of a committee trial of the new vaccine Grippovac SE-AZh].
In the trial of the trivalent subunit influenza vaccine Grippovac CE-AK observations on children aged 3-6 years were made. The preparation showed insignificant reactogenicity and moderate antigenic potency. The trial established that at the period of the epidemic rise of influenza B morbidity the vaccine showed, according to the data of the clinical diagnosis of influenza, insignificant effectiveness, its index of effectiveness (IE) being 1.08; according to the data of the serological diagnosis of influenza, only the A (H1N1) component of the vaccine was found to have IE equal to 1.58.
D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007114:Immunization; D009980:Influenza A virus / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D009031:Moscow; D012621:Seasons; D013997:Time Factors; D014505:Urban Population
D000914:Antibodies, Viral; D007252:Influenza Vaccines
Osnovnye itogi komissionnogo ispytaniia novoĭ vaktsiny "Grippovak SE-AZh".